Clinical Trials Directory

Trials / Conditions / Stage III Esophageal Cancer

Stage III Esophageal Cancer

11 registered clinical trials studyying Stage III Esophageal Cancer.

StatusTrialSponsorPhase
UnknownA Study of Creatine Combined With Curcumin in the Intervention of Early Cachexia in Upper Gastrointestinal Tum
NCT05856500
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolN/A
UnknownA Study to Compare Efficacy and Safety of DRT VS CRT Plus Surgery in Patients Who Achieved CCR for Esophageal
NCT03708042
Tianjin Medical University Cancer Institute and HospitalPhase 3
CompletedHealth Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
NCT03154190
Stanford UniversityN/A
UnknownA Phase II Trial to Compare Efficacy and Safety of CRT VS Neo-CRT in Patients Who Achieved CCR for Esophageal
NCT02959385
Tianjin Medical University Cancer Institute and HospitalPhase 2
CompletedSaracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Canc
NCT00607594
National Cancer Institute (NCI)Phase 2
CompletedOxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydroch
NCT01561014
Wake Forest University Health SciencesPhase 1
TerminatedA Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
NCT00064259
National Cancer Institute (NCI)Phase 1 / Phase 2
TerminatedArsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction
NCT00061958
National Cancer Institute (NCI)Phase 2
CompletedErlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer
NCT00045526
National Cancer Institute (NCI)Phase 2
CompletedErlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
NCT00030498
National Cancer Institute (NCI)Phase 1
CompletedInterleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
NCT00004074
National Cancer Institute (NCI)Phase 1